Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Guarente
Leonard Guarente, Newton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100105036 | SIR2 Activity - This invention relates to methods of screening compounds that modulate cellular and organismal processes by modification of the activity of SIR2 and/or transcription factors, e.g., p53, particularly methods of screening for compounds that modify lifespan and/or metabolism of a cell or an organism by modulation of the activity of SIR2 and/or transcription factors, e.g., p53, and more particularly to methods of screening for compounds that modulate the activity of Sir2 and/or transcription factors, e.g., p53. In particular, the present invention relates to a method for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound. The invention further relates to therapeutic uses of said compounds. The invention further relates to a method of modifying the acetylation status of a transcription factor binding site on histone or DNA by raising local concentrations of Sir2. | 04-29-2010 |
| 20100240029 | Cholesterol-Regulating Complex of SIRT1 and LXR and Methods of Use - A cholesterol-regulating complex of SIRT1 and LXR and methods of use are disclosed. SIRT1 forms a complex with LXR bound to an LXR element. Methods of forming the complex, identifying an agent that modulates formation of the complex, increasing the ratio of cholesterol bound to high density lipoprotein (HDL) to total cholesterol in the plasma of a mammal, promoting ABCA1-mediated cholesterol efflux from a mammalian cell, treating a subject deemed to have a level of SIRT1 activity that is below normal, assessing whether a candidate substance modulates an LXR-dependent process, and assessing whether a candidate substance modulates an SIRT1-dependent effect of an LXR are disclosed. | 09-23-2010 |
| 20110009474 | SIRTUIN BASED METHODS AND COMPOSITIONS FOR TREATING BETA-CATENIN-RELATED CONDITIONS - Provided herein are methods and compositions relating to sirtuin modulation of Wnt pathway signaling, including the use of sirtuin and sirtuin-modulating agents in the prevention and treatment of cancer and other diseases. | 01-13-2011 |
Leonard Guarente, Chestnut Hill, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090155834 | METHODS FOR IDENTIFYING AGENTS WHICH ALTER HISTONE PROTEIN ACETYLATION, DECREASE AGING OR INCREASE LIFESPAN - Methods of identifying agents which alter the NAD-dependent acetylation status and mono-ADP-ribosylation of nuclear proteins are disclosed. The methods further include identifying agents which alter the life span or aging of a cell or an organism by determining the level of NAD-dependent acetylation and/or ADP ribosylation of a nuclear protein. The invention also relates to a mammalian Sir2 protein which acetylates or deacetylates nuclear proteins in a NAD-dependent manner and has mono-ADP-ribosyltransferase activity. Host cells producing the Sir2 protein and antibodies to the Sir2 protein are also provided. | 06-18-2009 |
Leonard P. Guarente, Newton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110098190 | SIRT4 ACTIVITIES - Methods of screening for compounds that modulate the expression or activity of Sirt4 are provided. Also provided are methods of modulating insulin secretion, treating metabolic disorders, and treating neurodegenerative disorders by modulating the expression or activity of Sirt4. | 04-28-2011 |
Leonard P. Guarente, Chestnut Hill, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110218229 | SIRT1 Modulation of Adipogenesis and Adipose Function - SIRT1 regulates the physiology of cells of the adipocyte lineage. Modulators of SIRT1 activity can be used to ameliorate, treat, or prevent diseases and disorders associated with adipose physiology, e.g., obesity, an obesity-related disease, or a fat-related metabolic disorder. | 09-08-2011 |